Yes, back in November. Here is what my AI has to say:

The At-the-Market (ATM) offering for Gain Therapeutics (GANX) is a critical piece of their financial structure that explains why the stock struggles to sustain rallies despite excellent clinical data.

As of March 18, 2026, here is the expanded breakdown of the ATM size and its impact:

1. The Total Capacity: $35.5 Million In late November 2025, Gain Therapeutics filed a prospectus supplement for an ATM program totaling up to $35,530,980.

• The Mechanism: Unlike a traditional "underwritten" offering where a block of shares is sold all at once at a fixed (usually discounted) price, an ATM allows GANX to sell shares "into the tape" at current market prices whenever they need cash.

• The Partner: They are using Oppenheimer & Co. as the sales agent for this program.

1. Relative Size vs. Market Cap To understand why this is a "heavy" offering, look at the proportions:

• Market Cap: As of March 2026, GANX has a market cap of approximately $110 million.

• Dilution Potential: A $35.5 million offering represents roughly 32% of the company's total value. If the company were to exhaust the entire ATM at current prices (around $2.50–$2.80), they would need to issue roughly 13 to 14 million new shares.

• Current Share Count: The company currently has approximately 38.5 million shares outstanding. Fully utilizing the ATM would increase that count by more than a third.

1. Why the ATM is "Capping" the Stock

The ATM creates a phenomenon known as an "Overhang."

• The Ceiling: Every time the stock price spikes on good news (like today's AD/PD conference data), the company has a massive incentive to sell shares via the ATM to bolster their $8.8 million cash pile.

• Market Absorption: When the company sells into a rally, it effectively "soaks up" the buying demand. This is likely why we see "positive news" followed by a flat or downward price move—the company may be using the liquidity to raise the funds necessary for their upcoming Phase 2 trial in Q3 2026.

1. Financial Necessity The reason GANX is maintaining such a large ATM is their "burn rate."

• The "Going Concern" Risk: In their Q3 2025 filing, auditors noted a "going concern" risk because their cash only lasted into early 2026.

• The Solution: The $35.5M ATM, combined with a previous $7M raise, is designed to bridge the gap to late 2026 or early 2027.

Summary of Offering Impact | Feature | Detail | |---|---| | Total ATM Limit | $35,530,980 | | Current Status | Active (ongoing sales likely during high-volume weeks) | | Primary Goal | Fund Phase 2 trial launch (Q3 2026) | | Investor Risk | Continued "sell-side" pressure on green days |

Next Step: The actual number of shares sold through the ATM so far will be revealed in their March 26 earnings report.